Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Epoetin alfa 4,000units/0.4ml inj pre-filled syringes
0901030D0AAAKAK
|
Epoetin alfa | Epoetin alfa | Nutrition and Blood | 16 |
|
Epoetin beta 10,000units/0.6ml inj pre-filled syringes
0901030E0AAATAT
|
Epoetin beta | Epoetin beta | Nutrition and Blood | 16 |
|
Fresubin 1500 Complete liquid
0914011C0BBAAAB
|
Fresubin tube feed 1 kcal/ml with fibre | Tube feed 1 kcal/ml with fibre (0914011) | Nutrition and Blood | 16 |
|
MagnEss Gly 121.25mg/5ml (5mmol/5ml) oral solution
0905013G0BHAFDK
|
MagnEss Gly | Magnesium glycerophosphate | Nutrition and Blood | 16 |
|
Nutricia Hydrolysed protein powder
0913391A0BCAAAC
|
Nutricia pdr disc or non ACBS energy and protein fortifier | Pdr disc or non ACBS energy and protein fortifier (0913391) | Nutrition and Blood | 16 |
|
Nutrison Protein Advance liquid
0914071A0BBABAB
|
Nutrison tube feed non ACBS 1.3kcal/ml h/prot for use in IC | Tube feed non ACBS 1.3kcal/ml h/prot for use in IC (0914071) | Nutrition and Blood | 16 |
|
Premier Multivitamin & Mineral capsules
091000000BBKGBT
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | 16 |
|
Solgar Vitamin B12 1000microgram sublingual nuggets
0901020D0BGAAAI
|
Solgar Vitamin B12 | Cyanocobalamin | Nutrition and Blood | 16 |
|
TYR Easy tablets
0913206H0BBAAAA
|
TYR tablet 73g protein equivalent per 100g | Tablet 73g protein equivalent per 100g (0913206) | Nutrition and Blood | 16 |
|
TYR sphere20 oral powder 35g sachets vanilla
0913206F0BBABAA
|
TYR ready to serve 20g GMP protein equivalent | Ready to serve 20g GMP protein equivalent (0913206) | Nutrition and Blood | 16 |
|
Alfacalcidol 1micrograms/0.5ml inj ampoules
0906040B0AAAFAF
|
Alfacalcidol | Alfacalcidol | Nutrition and Blood | 15 |
|
AlfaD 0.5microgram capsules
0906040B0BEABAI
|
AlfaD | Alfacalcidol | Nutrition and Blood | 15 |
|
Aviticol 20,000unit capsules
0906040G0DJAADR
|
Aviticol | Colecalciferol | Nutrition and Blood | 15 |
|
Betacarotene 15mg capsules
0906012B0AAACAC
|
Betacarotene | Betacarotene | Nutrition and Blood | 15 |
|
Betaine 500mg tablets
0908010T0AAAAAA
|
Betaine anhydrous | Betaine anhydrous | Nutrition and Blood | 15 |
|
Cholesterol 1g oral powder sachets
0908010D0AAALAL
|
Cholesterol | Cholesterol | Nutrition and Blood | 15 |
|
ColeDose D3 800unit tablets
0906040G0ECAECS
|
ColeDose D3 | Colecalciferol | Nutrition and Blood | 15 |
|
Cubicole D3 600unit capsules
0906040G0CKABBF
|
Cubicole D3 | Colecalciferol | Nutrition and Blood | 15 |
|
Cystine500 oral powder sachets
0913213A0BEAAAD
|
Cystine500 powder single L-amino acid supplement | Powder single L-amino acid supplement (0913213) | Nutrition and Blood | 15 |
|
Darbepoetin alfa 20micrograms/0.5ml inj pre-filled syringes
0901030J0AAAEAE
|
Darbepoetin alfa | Darbepoetin alfa | Nutrition and Blood | 15 |
|
Efamol Efalex Brain Formula liquid
091200000BDGDFR
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | 15 |
|
EnergieShake 2.0kcal liquid (3 flavours)
0913011S0BCAAAH
|
EnergieShake RtS 2-2.4 kcal/ml m/sk higher prot,high energy | RtS 2-2.4 kcal/ml m/sk higher protein,higher energy(0913011) | Nutrition and Blood | 15 |
|
FerroDose-F 210mg tablets
0901011F0BGAAAE
|
FerroDose-F | Ferrous fumarate | Nutrition and Blood | 15 |
|
Filgrastim 30million units/0.5ml inj pre-filled syringes
0901060I0AAALAL
|
Filgrastim | Filgrastim | Nutrition and Blood | 15 |
|
Glytactin Build 20/20 oral powder 32g sachets chocolate
0913205E0BCAEAC
|
Glytactin powder 20g GMP protein equivalent | Powder 20g GMP protein equivalent (0913205) | Nutrition and Blood | 15 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.